A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
← catalyst calendarNCT07195916 · readout in 730 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
280estimated
Sites
22
Countries
Australia, Belgium, Denmark +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-08 | actual | When the study began enrolling |
| Primary completion | 2028-08-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-18 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Solid Tumors
- Hematologic Malignancies
Intervention
- Drug: INCA036873
Primary outcomes
what the primary-completion date above is the date OFPart 1A : Occurrence of Dose Limiting Toxicities (DLTs)
measured Up to Day 28
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
measured Up to approximately 2 years and 90 days
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed